1mu6

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
Recent efforts in the field of thrombin inhibitor research have focused on, the identification of compounds with good oral bioavailability and, pharmacokinetics. In this manuscript we describe a metabolism-based, approach to the optimization of the, 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which, resulted in the modification of each of the three principal components, (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified, which exhibit high levels of oral bioavailability and long plasma, half-lives.
+
Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.
==Disease==
==Disease==
Line 17: Line 17:
[[Category: Protein complex]]
[[Category: Protein complex]]
[[Category: Thrombin]]
[[Category: Thrombin]]
-
[[Category: Barrow, J.C.]]
+
[[Category: Barrow, J C.]]
[[Category: Bohn, D.]]
[[Category: Bohn, D.]]
-
[[Category: Burgey, C.S.]]
+
[[Category: Burgey, C S.]]
[[Category: Chen, Z.]]
[[Category: Chen, Z.]]
-
[[Category: Clayton, F.C.]]
+
[[Category: Clayton, F C.]]
-
[[Category: Coburn, C.A.]]
+
[[Category: Coburn, C A.]]
-
[[Category: Cook, J.J.]]
+
[[Category: Cook, J J.]]
-
[[Category: Dorsey, B.D.]]
+
[[Category: Dorsey, B D.]]
-
[[Category: Gardell, S.J.]]
+
[[Category: Gardell, S J.]]
-
[[Category: Holahan, M.A.]]
+
[[Category: Holahan, M A.]]
-
[[Category: Jr., J.J.Lynch.]]
+
[[Category: Jr., J J.Lynch.]]
-
[[Category: Jr., T.J.Detwiler.]]
+
[[Category: Jr., T J.Detwiler.]]
-
[[Category: Krueger, J.A.]]
+
[[Category: Krueger, J A.]]
[[Category: Kuo, L.]]
[[Category: Kuo, L.]]
-
[[Category: Leonard, Y.M.]]
+
[[Category: Leonard, Y M.]]
-
[[Category: Lewis, S.D.]]
+
[[Category: Lewis, S D.]]
-
[[Category: Lucas, B.J.]]
+
[[Category: Lucas, B J.]]
-
[[Category: Lyle, E.A.]]
+
[[Category: Lyle, E A.]]
-
[[Category: Lyle, T.A.]]
+
[[Category: Lyle, T A.]]
-
[[Category: McDonough, C.M.]]
+
[[Category: McDonough, C M.]]
-
[[Category: McMasters, D.R.]]
+
[[Category: McMasters, D R.]]
[[Category: Miller-Stein, C.]]
[[Category: Miller-Stein, C.]]
-
[[Category: Robinson, K.A.]]
+
[[Category: Robinson, K A.]]
-
[[Category: Sanders, W.M.]]
+
[[Category: Sanders, W M.]]
-
[[Category: Sanderson, P.E.]]
+
[[Category: Sanderson, P E.]]
-
[[Category: Shafer, J.A.]]
+
[[Category: Shafer, J A.]]
[[Category: Singh, R.]]
[[Category: Singh, R.]]
-
[[Category: Sitko, G.R.]]
+
[[Category: Sitko, G R.]]
-
[[Category: Stranieri, M.T.]]
+
[[Category: Stranieri, M T.]]
-
[[Category: Vacca, J.P.J.]]
+
[[Category: Vacca, J P.J.]]
-
[[Category: Wallace, A.A.]]
+
[[Category: Wallace, A A.]]
-
[[Category: White, R.B.]]
+
[[Category: White, R B.]]
-
[[Category: Williams, P.D.]]
+
[[Category: Williams, P D.]]
[[Category: Wong, B.]]
[[Category: Wong, B.]]
[[Category: Yan, Y.]]
[[Category: Yan, Y.]]
Line 56: Line 56:
[[Category: hydrolase]]
[[Category: hydrolase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:25:49 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:59:07 2008''

Revision as of 11:59, 21 February 2008


1mu6, resolution 1.99Å

Drag the structure with the mouse to rotate

Crystal Structure of Thrombin in Complex with L-378,622

Contents

Overview

Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.

Disease

Known diseases associated with this structure: Dysprothrombinemia OMIM:[176930], Hyperprothrombinemia OMIM:[176930], Hypoprothrombinemia OMIM:[176930]

About this Structure

1MU6 is a Protein complex structure of sequences from Homo sapiens with as ligand. Active as Thrombin, with EC number 3.4.21.5 Full crystallographic information is available from OCA.

Reference

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines., Burgey CS, Robinson KA, Lyle TA, Sanderson PE, Lewis SD, Lucas BJ, Krueger JA, Singh R, Miller-Stein C, White RB, Wong B, Lyle EA, Williams PD, Coburn CA, Dorsey BD, Barrow JC, Stranieri MT, Holahan MA, Sitko GR, Cook JJ, McMasters DR, McDonough CM, Sanders WM, Wallace AA, Clayton FC, Bohn D, Leonard YM, Detwiler TJ Jr, Lynch JJ Jr, Yan Y, Chen Z, Kuo L, Gardell SJ, Shafer JA, Vacca JP, J Med Chem. 2003 Feb 13;46(4):461-73. PMID:12570369

Page seeded by OCA on Thu Feb 21 13:59:07 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools